指南推荐与新型药物在2型糖尿病管理中的定位
本文关注ADA/EASD共识报告与ESC指南之间关于2型糖尿病管理差异的讨论可能导致临床惰性。来自两个写作组的成员召开会议,强调共同点并提出整合框架,以确保合并心血管疾病、心衰或慢性肾病的2型糖尿病患者接受SGLT2抑制剂或GLP-1受体激动剂治疗,且独立于背景治疗、当前血糖控制或个体化治疗目标。
要点
- ADA/EASD共识与ESC指南的差异讨论不应导致临床惰性。
- 合并心血管疾病、心衰或慢性肾病的2型糖尿病患者应接受SGLT2抑制剂或GLP-1受体激动剂。
- 启动SGLT2抑制剂或GLP-1受体激动剂应独立于背景治疗、血糖控制或个体化目标。
核心结论
- 需要协调行动以确保合并心血管疾病、心衰或慢性肾病的2型糖尿病患者接受SGLT2抑制剂或GLP-1受体激动剂的适当治疗。
- 启动SGLT2抑制剂或GLP-1受体激动剂应独立于背景治疗、当前血糖控制或个体化治疗目标。
研究设计与样本
- 来自ADA-EASD共识报告和ESC指南写作组的部分成员召开会议,强调共同点并提出整合框架。
主要发现
- 对ADA/EASD共识报告与ESC指南差异的持续讨论可能导致临床惰性,使患者无法获得两组均倡导的循证治疗。
关键数值与推荐
- 合并心血管疾病、心衰或慢性肾病的2型糖尿病患者应接受SGLT2抑制剂或GLP-1受体激动剂治疗。
临床怎么用
- 临床医生应确保合并心血管疾病、心衰或慢性肾病的2型糖尿病患者接受SGLT2抑制剂或GLP-1受体激动剂,启动时不考虑背景治疗、当前血糖控制或个体化治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk have led to remarkable advances in our understanding of the effectiveness of GLP-1 receptor agonists and SGLT2 inhibitors to reduce cardiorenal events. In 2019, the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and European Society of Cardiology (ESC) published updated recommendations for the management of such patients. We are concerned that ongoing discussions focusing on the differences between the endocrinologists' consensus report from the ADA and EASD and cardiologists' guidelines from the ESC are contributing to clinical inertia, thereby effectively denying evidence-based treatments advocated by both groups to patients with type 2 diabetes and cardiorenal disease. A subset of members from the writing groups of the ADA-EASD consensus report and the ESC guidelines was convened to emphasise where commonalities exist and to propose an integrated framework that encompasses the views incorporated in management approaches proposed by the ESC and the ADA and EASD. Coordinated action is required to ensure that people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease are treated appropriately with an SGLT2 inhibitor or GLP-1 receptor agonist. In our opinion, this course should be initiated independent of background therapy, current glycaemic control, or individualised treatment goals.
引用
- Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2020. PMID: 33159841. doi:10.1016/S2213-8587(20)30343-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。